Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma

L. F. Porrata, M. R. Lotzow, D. J. Inwards, D. A. Gastineau, S. B. Moore, A. A. Pineda, K. L. Bundy, D. J. Padley, D. Persky, Stephen Maxted Ansell, I. N M Micaleef, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r = 0.71). A higher A-ALC was infused into patients achieving an ALC-15 ≥500/μl vs ALC-15 <500/μl (median of 0.68 × 109/kg (0.04-2.21 × 109/kg), vs 0.34 × 109/kg (0.04-1.42 × 109/kg), P < 0.0001). The median follow-up for all patients was 36 months (maximum of 109 months). The A-ALC threshold was determined at 0.5 × 109/kg. The median overall survival (OS) and progression-free survival (PFS) times were longer in patients who received an A-ALC ≥ 0.5 × 109/kg vs A-ALC <0.5 × 109/kg (76 vs 17 months, P < 0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.

Original languageEnglish (US)
Pages (from-to)291-298
Number of pages8
JournalBone Marrow Transplantation
Volume33
Issue number3
DOIs
StatePublished - Feb 2004

Fingerprint

Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Autografts
Lymphocyte Count
Non-Hodgkin's Lymphoma
Lymphocytes
Survival
Disease-Free Survival
Multivariate Analysis

Keywords

  • Absolute lymphocyte recovery
  • Autologous peripheral blood hematopoietic stem cell transplantation
  • Infused peripheral blood autograft absolute lymphocyte count

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. / Porrata, L. F.; Lotzow, M. R.; Inwards, D. J.; Gastineau, D. A.; Moore, S. B.; Pineda, A. A.; Bundy, K. L.; Padley, D. J.; Persky, D.; Ansell, Stephen Maxted; Micaleef, I. N M; Markovic, Svetomir Nenad.

In: Bone Marrow Transplantation, Vol. 33, No. 3, 02.2004, p. 291-298.

Research output: Contribution to journalArticle

Porrata, L. F. ; Lotzow, M. R. ; Inwards, D. J. ; Gastineau, D. A. ; Moore, S. B. ; Pineda, A. A. ; Bundy, K. L. ; Padley, D. J. ; Persky, D. ; Ansell, Stephen Maxted ; Micaleef, I. N M ; Markovic, Svetomir Nenad. / Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 3. pp. 291-298.
@article{8a5e74f2d39a4be4bc1d0f4b2e6798e2,
title = "Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma",
abstract = "Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r = 0.71). A higher A-ALC was infused into patients achieving an ALC-15 ≥500/μl vs ALC-15 <500/μl (median of 0.68 × 109/kg (0.04-2.21 × 109/kg), vs 0.34 × 109/kg (0.04-1.42 × 109/kg), P < 0.0001). The median follow-up for all patients was 36 months (maximum of 109 months). The A-ALC threshold was determined at 0.5 × 109/kg. The median overall survival (OS) and progression-free survival (PFS) times were longer in patients who received an A-ALC ≥ 0.5 × 109/kg vs A-ALC <0.5 × 109/kg (76 vs 17 months, P < 0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.",
keywords = "Absolute lymphocyte recovery, Autologous peripheral blood hematopoietic stem cell transplantation, Infused peripheral blood autograft absolute lymphocyte count",
author = "Porrata, {L. F.} and Lotzow, {M. R.} and Inwards, {D. J.} and Gastineau, {D. A.} and Moore, {S. B.} and Pineda, {A. A.} and Bundy, {K. L.} and Padley, {D. J.} and D. Persky and Ansell, {Stephen Maxted} and Micaleef, {I. N M} and Markovic, {Svetomir Nenad}",
year = "2004",
month = "2",
doi = "10.1038/sj.bmt.1704355",
language = "English (US)",
volume = "33",
pages = "291--298",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma

AU - Porrata, L. F.

AU - Lotzow, M. R.

AU - Inwards, D. J.

AU - Gastineau, D. A.

AU - Moore, S. B.

AU - Pineda, A. A.

AU - Bundy, K. L.

AU - Padley, D. J.

AU - Persky, D.

AU - Ansell, Stephen Maxted

AU - Micaleef, I. N M

AU - Markovic, Svetomir Nenad

PY - 2004/2

Y1 - 2004/2

N2 - Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r = 0.71). A higher A-ALC was infused into patients achieving an ALC-15 ≥500/μl vs ALC-15 <500/μl (median of 0.68 × 109/kg (0.04-2.21 × 109/kg), vs 0.34 × 109/kg (0.04-1.42 × 109/kg), P < 0.0001). The median follow-up for all patients was 36 months (maximum of 109 months). The A-ALC threshold was determined at 0.5 × 109/kg. The median overall survival (OS) and progression-free survival (PFS) times were longer in patients who received an A-ALC ≥ 0.5 × 109/kg vs A-ALC <0.5 × 109/kg (76 vs 17 months, P < 0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.

AB - Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in non-Hodgkin's lymphoma (NHL). Factors affecting ALC-15 remain unknown. We hypothesized that dose of infused autograft lymphocytes (A-ALC) directly impacts upon ALC-15. A total of 190 consecutive NHL patients received A-ALC between 1993 and 2001. The primary end point was correlation between A-ALC and ALC-15. A strong correlation was identified (r = 0.71). A higher A-ALC was infused into patients achieving an ALC-15 ≥500/μl vs ALC-15 <500/μl (median of 0.68 × 109/kg (0.04-2.21 × 109/kg), vs 0.34 × 109/kg (0.04-1.42 × 109/kg), P < 0.0001). The median follow-up for all patients was 36 months (maximum of 109 months). The A-ALC threshold was determined at 0.5 × 109/kg. The median overall survival (OS) and progression-free survival (PFS) times were longer in patients who received an A-ALC ≥ 0.5 × 109/kg vs A-ALC <0.5 × 109/kg (76 vs 17 months, P < 0.0001; 49 vs 10 months, P<0.0001, respectively). Multivariate analysis demonstrated A-ALC to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that ALC-15 and survival are dependent upon the dose of infused A-ALC in NHL.

KW - Absolute lymphocyte recovery

KW - Autologous peripheral blood hematopoietic stem cell transplantation

KW - Infused peripheral blood autograft absolute lymphocyte count

UR - http://www.scopus.com/inward/record.url?scp=10744226246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744226246&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704355

DO - 10.1038/sj.bmt.1704355

M3 - Article

C2 - 14676784

AN - SCOPUS:10744226246

VL - 33

SP - 291

EP - 298

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -